A companion to the reading
Evidence boundaries
A finding has a setting: the people studied, the activity around it, the preparation examined and the kind of record being read. These four examples keep those details beside the finding so that a claim does not become broader as it moves from a paper or label to a product page.
This reader contains fixed source examples and does not ask for or save health answers. It does not assess symptoms, interpret laboratory results, establish eligibility, clear pregnancy or kidney concerns, or recommend a dose, loading phase, schedule or course. Published amounts and durations identify records; they are not instructions. Personal decisions require an appropriate qualified professional, and manufacturer or account correspondence is not a substitute for clinical care.
Explore the four records
A result in nineteen young women
What was examined
The primary abstract of a 1997 randomized study describes nineteen young female volunteers undertaking ten weeks of resistance training. Creatine was compared with placebo in that setting. The abstract is the record examined here; it provides a narrower view than a complete review of the trial methods and safety information.
What was reported
The abstract reports larger improvements with creatine in maximal strength of the trained muscle groups, intermittent exercise capacity of the arm flexors and fat-free mass. These are the particular outcomes reported from this small training study, rather than a finding about every aspect of women’s health.
Where the finding stops
Young volunteers in a resistance-training study do not represent all women who encounter a supplement advertisement. The result does not establish a response after menopause, validate a current retail blend or predict an individual benefit. Neither the study’s duration nor its protocol is a personal course to follow.
A question for the professional
Which features of the participants, comparison and measured outcome would matter when discussing the claim I have encountered? What evidence would be needed before applying this small study to a different group or a named finished product?
Different outcomes within the same exercise program
What was examined
A full 2023 paper reports a two-year trial that randomized 237 postmenopausal women, with a mean age of 59. Both creatine and placebo groups participated in resistance training and walking and received calcium and vitamin D. Femoral-neck bone mineral density was the primary outcome; the study examined an addition to this shared research program.
What was reported
Creatine did not add a benefit for femoral-neck, hip or spine bone density, or the tested bench-press and hack-squat strength measures. Some bone-geometry measures favored creatine, and the timed 80-meter walk improved relative to placebo. An additional lean-tissue increase appeared only in the valid-completers analysis, not the main analysis of all randomized participants or the adherence-based analysis.
Where the finding stops
The mixed findings do not establish fracture prevention, lasting independence or the effects of buying a particular powder. The paper identifies attrition and relatively low adherence as limitations. A finding confined to one analysis cannot be presented as the result for everyone randomized, and the shared exercise setting cannot disappear from the interpretation.
A question for the professional
Which of these outcomes addresses the concern being discussed, and which findings leave that concern unanswered? How should the main result, the narrower lean-tissue analysis and the study limitations affect the way we interpret a supplement claim?
Two unflavored powders with different declarations
What was examined
The current US Optimum Nutrition Micronized Creatine Powder panel for the unflavored sixty-serving version and the Transparent Labs Creatine HMB panel for the unflavored thirty-serving version are separate public product records. Their online ingredient declarations were read; no delivered container was opened or independently assayed.
What was reported
The selected ON panel declares creatine monohydrate and no other ingredients. The selected TL panel also declares HMB, vitamin D, calcium and BioPerine black-pepper extract. These labels document different advertised formulas. The word unflavored describes neither an identical preparation nor a result in women.
Where the finding stops
NIH cautions against predicting a combination’s effects and safety from studies of its individual ingredients when that particular combination has not been studied. A formula declaration is also different from authenticating a supplied lot. These records establish neither an advantage for the blend nor a clinical preference for the simpler declaration.
A question for the professional
What evidence connects the exact preparation being considered to the claim, and what information about its full formula would a qualified professional need? Which questions concern a clinical decision, and which require clarification of the manufacturer’s product record?
A bundle description is a financial record
What was examined
The current Strong Suit offer describes a dietary supplement with one-time bundles and optional Refill Protection. Its commercial month labels sit beside totals and serving counts. The same public panel leaves an unexplained difference between the declared scoop mass and creatine quantity, despite listing no other ingredients; this reader does not supply a corrected label.
What was reported
The advertised options are $228 for twelve months and 360 servings, $149.94 for six months and 180 servings, $87 for three months and ninety servings, and $39 for one month and thirty servings. The corresponding displayed monthly amounts are $19, $24.99, $29 and $39. Optional refills and shipping have separate conditions, and no checkout was completed.
Where the finding stops
Neither a serving count nor a commercial period determines an amount or length of use for an individual. The monthly equivalent does not establish monthly billing, and a box description does not establish the number of tubs supplied. FDA’s supplement category provides no premarket safety-and-effectiveness approval; buying a bundle cannot settle a personal health question.
A question for the professional
Before a purchase decision, which health questions belong with a qualified professional, and which product or agreement details need an answer from the seller? How can the advertised commitment remain separate from any discussion about whether supplementation has a relevant purpose?